Tarsus Q1 net loss $23.4M; cash $201.2M; TP-03 PDUFA Aug 25

Tarsus Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.88 revenue$2,500,000

Net loss of $23.4M vs $20.2M in Q1 2022; revenue $2.5M from LianBio partnership.
Cash and marketable securities $201.2M as of March 31, 2023.
TP-03 (Demodex blepharitis) PDUFA date August 25, 2023; 93% of eye doctors would prescribe if approved.
Phase 2a trials ongoing for TP-04 (rosacea), TP-05 (Lyme prevention), and TP-03 (MGD).
Appointed Jeff Farrow as CFO and Chief Strategy Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tarsus Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the three months ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Tarsus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001819790-23-000028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.